| ★ |  GDF2026 - ICH M13A High-Risk vs. Low-Risk Case Studies – Bioequivalence (BE) Implications | U.S. Food and Drug Administration @us_fda | 251 | Estados Unidos | |
| 15 |  GDF2026 - Manufacturing Deficiencies in Liquid Drug Products: The Top Ten Issues | U.S. Food and Drug Administration @us_fda | 602 | Estados Unidos | 89 |
| 14 |  GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals | U.S. Food and Drug Administration @us_fda | 409 | Estados Unidos | 89 |
| 4 |  GDF2026 - Quality and Safety Assessment of Extractables/Leachables in Generic Drug Products | U.S. Food and Drug Administration @us_fda | 363 | Estados Unidos | 91 |
| 8 |  GDF2026 - Q&A Discussion Panel Eight | U.S. Food and Drug Administration @us_fda | 298 | Estados Unidos | 90 |
| 16 |  GDF2026 - Q&A Discussion Panel Six | U.S. Food and Drug Administration @us_fda | 292 | Estados Unidos | 89 |
| 3 |  GDF2026 - Bioanalysis of Endogenous Drugs Using Surrogate Matrix Approach in ANDAs | U.S. Food and Drug Administration @us_fda | 279 | Estados Unidos | 92 |
| 20 |  GDF2026 - Data Integrity in ANDA Applications | U.S. Food and Drug Administration @us_fda | 189 | Estados Unidos | 89 |
| 1 |  GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations | U.S. Food and Drug Administration @us_fda | 160 | Estados Unidos | 93 |
| 11 |  GDF2026 - Regulatory Review Process for Type II Secondary DMFs | U.S. Food and Drug Administration @us_fda | 142 | Estados Unidos | 90 |
| 19 |  GDF2026 - Q&A Discussion Panel Two | U.S. Food and Drug Administration @us_fda | 136 | Estados Unidos | 89 |
| 5 |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | 91 |
| 9 |  GDF2026 - An Update on CDER’s Quality Management Maturity (QMM) Program | U.S. Food and Drug Administration @us_fda | 109 | Estados Unidos | 90 |
| 18 |  GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides | U.S. Food and Drug Administration @us_fda | 86 | Estados Unidos | 89 |
| 7 |  GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 90 |
| 6 |  GDF2026 - Standardized Principles Used to Determine Maximum Daily Dose | U.S. Food and Drug Administration @us_fda | 57 | Estados Unidos | 90 |
| 13 |  GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 89 |
| 2 |  GDF2026 - Common Bioequivalence (BE) Study Design Deficiencies and How to Avoid Them | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 92 |
| 10 |  GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 90 |
| 17 |  GDF2026 - Suitability Petitions | U.S. Food and Drug Administration @us_fda | 41 | Estados Unidos | 89 |
| 12 |  GDF2026 - Q&A Discussion Panel One | U.S. Food and Drug Administration @us_fda | 19 | Estados Unidos | 90 |